2022 Development Timelines
1AD - 2022 Goals
Significantprogress anticipated on both existing core programs and further pipelineexpansion
AD-214 – First in class anti-fibrotic
• Inhaledformulation development: nebulisation feasibility, efficacy in animal model ofIPF (Q1); lung distribution imaging in healthy and disease model animals (Q1);dose finding and clinical formulation (Q2)
• Intravenousformulation development (Q3)
• GLP toxicologywith inhaled formulation (commences 2H22)
• Continuing partneringdiscussions (Q1); selection of next indication
GE Healthcare – GZMB PET imaging
• Pre-clinicalproof of concept – milestone payment (mid-22)
Carina Biotech – i-body enabled CAR-T cells
• 1stexperimental results on Target #1
• Commencei-body discovery on Target #2
Internal pipeline and platform development
• Initialfunctional data on i-body binders against internal Target #2 (2H22)
• i-body2.0: newintellectual property filed (end’22)
• 7 programs inpipeline (end’22)
• Additionalpatent filings, grants on individual i-body enabled products
- Forums
- ASX - By Stock
- 1AD
- 1AD 2022 Development Timelines
1AD 2022 Development Timelines
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.89M |
Open | High | Low | Value | Volume |
2.5¢ | 2.5¢ | 2.5¢ | $11.70K | 468.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500000 | 2.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 107132 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500000 | 0.024 |
1 | 29010 | 0.023 |
2 | 90650 | 0.022 |
2 | 1047615 | 0.021 |
2 | 526797 | 0.020 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 107132 | 2 |
0.026 | 520037 | 3 |
0.027 | 200000 | 1 |
0.028 | 104333 | 2 |
0.034 | 10000 | 1 |
Last trade - 15.42pm 12/07/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |